PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Reducing PNPLA3-I148M protein levels in the liver, including with I148M-specific siRNA, reduces fatty liver disease phenotypes, supporting a specific role for PNPLA3-I148M in driving MASLD (15, –17).